Navigation Links
Publication in Clinical Cancer Research Confirms Ability of Peregrine's Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
Date:3/3/2008

or activity seen to date with bavituximab," said Dr. Thorpe, professor of pharmacology at UT Southwestern and a member of Peregrine's Scientific Resource Board. "Bavituximab's ability to achieve unusually clear images of tumors in living animals also suggests that it might have utility for the non-invasive imaging of tumors in cancer patients. Although the study was conducted in rats bearing prostate tumors, we expect that the observations will extend to other solid tumor types as well."

In the study, researchers administered radiolabeled bavituximab to rats with prostate tumors and then conducted molecular imaging studies of the rats over the next several days. The results showed that radiolabeled bavituximab localized to the tumor blood vessels with great specificity. In these subjects, 22 times as much bavituximab localized to the tumor compared to the liver when measured 72 hours post-injection. The study further showed no specific localization of bavituximab to blood or other tissues including the heart, kidney, intestine, muscle, bone and brain. The tumor blood vessel-selective targeting observed in vivo in the study was confirmed by further bio-distribution analyses and by histology studies.

"This important new peer-reviewed study reinforces earlier evidence that bavituximab targets tumor blood vessels with excellent specificity," said Steven W. King, president and CEO of Peregrine. "As we continue to advance the cancer clinical program for bavituximab, these types of studies are expanding the body of scientific evidence demonstrating the highly specific nature of bavituximab's ability to target PS on tumor blood vessels."

Bavituximab is a monoclonal antibody that binds to a phospholipid called phosphatidylserine that is usually located inside normal cells, but which becomes exposed on the outside of the cells that line the blood vessels of tumors, creating a specific target for anti-cancer treatments. Bavituximab is believed to help mobi
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Ortho Biotech Statement On JAMA Publication Regarding Erythropoiesis-Stimulating Agents
2. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy
3. BioTrends Releases Fourth Annual Nephrology TreatmentTrends Publication Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
4. Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Cyclophosphamide Treatment
5. Research by Case Western Reserve University, VA earns cover of prestigious science publication
6. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
7. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
8. Industry Executives Finding Value in Shift of Scientific Publications
9. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
10. Nventa announces publication of HspE7 data
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  CorMedix Inc. (NYSE ... and commercializing therapeutic products for the prevention and ... receipt of notice on July 18, 2014 from ... has accepted the CorMedix plan to regain compliance ... a result, the NYSE-MKT is continuing the Company,s ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... The first part of the session on ... Human Studies” will cover comprehensive clinical support in early ... increasing R&D costs and declining industry success in getting ... knowledge collected in early Phase I/IIa study data to ... stage development. , Next, the presenters will examine steps ...
(Date:7/24/2014)... , July 24, 2014   Cypher ... today the appointment of Adam Simpson ... Genomics provides rapid and comprehensive annotation and interpretation ... clinical reporting. "Cypher,s technology has the ... healthcare by enhancing diagnostic accuracy, optimizing therapeutic approaches ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... in the sensitivity of weighing scales. Using the same ... functional nanotube radio, researchers with Berkeley Lab and the ... nanoelectromechanical system (NEMS) that can function as a scale ... atom of gold. , Alex Zettl, a physicist who ...
... SAN DIEGO, July 28 Ardea Biosciences, Inc.,(Nasdaq: ... be presented on RDEA806, the,Company,s novel investigational non-nucleoside ... virus (HIV) at,the 48th Annual ICAAC/IDSA 46th Annual ... Dr. Graeme Moyle, Director of HIV Research, Chelsea ...
... at IMAPS 2008 , ... Washington, D.C. (PRWEB) July ... proud to announce that Governor Carcieri and Dr Zolper have agreed ... on Microelectronics (IMAPS ,08) at the Providence, RI, Convention Center, November ...
Cached Biology Technology:Golden scales 2Golden scales 3Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 2Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting 3Rhode Island Governor Donald L. Carcieri and Dr. John C. Zolper, Vice President, Raytheon Company to Speak at IMAPS 2008 2
(Date:7/24/2014)... cars ply silent freeways, solar panels blanket rooftops and ... from howling winds and from the blazing desert sun. ... technically and economically feasible to convert California,s all-purpose energy ... in Energy , the plan shows the way ... California that could create tens of thousands of jobs ...
(Date:7/24/2014)... research out of York University shows a surprisingly effective ... grass fungus: moose saliva (yes moose saliva). , ... saliva inhibits a grassendophyte mutualism" shows that moose and ... hosts a fungus called epichlo festucae that produces the ... toxicity. , "Plants have evolved defense mechanisms to protect ...
(Date:7/24/2014)... team of researchers has developed a new nanoscale agent ... method for assessing the function and properties of the ... diagnosis and treatment of gut diseases. , ... syndrome and inflammatory bowel disease all occur in the ... patients with diseases such as diabetes and Parkinson,s. ...
Breaking Biology News(10 mins):Stanford study shows how to power California with wind, water and sun 2Stanford study shows how to power California with wind, water and sun 3Stanford study shows how to power California with wind, water and sun 4Moose drool inhibits growth of toxic fungus: York U research 2New imaging agent provides better picture of the gut 2
... children and young adults for influenza is being seriously underestimated, ... historic vaccine programs have concentrated on the elderly and those ... computer modeling analysis was just published in the journal ... Health. The study suggests that children in school and young ...
... June 11, 2013 (BRONX, NY) Today, researchers ... Yeshiva University convened a one-day conference on Jewish genetics ... research. Such research could help scientists identify causes and ... common disorders afflicting the general population. The ...
... guarantee future support for international scientific collaborations funded by ... on a three year budgetary framework will extend the ... At an Intergovernmental Conference hosted by the European Commission ... governments that support the Human Frontier Science Program came ...
Cached Biology News:Flu vaccines aimed at younger populations could break annual transmission cycle 2Flu vaccines aimed at younger populations could break annual transmission cycle 3Albert Einstein College of Medicine hosts conference on Jewish genetic research 2
...
Request Info...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Adducin beta (C-16)...
Biology Products: